Regulatory reforms that improve the competitive landscape for biosimilars will promote drug affordability while incentivizing ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Biosimilars can not only reduce patients' financial burdens, but also encourage more people to go for early diagnosis and ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

The company isn't content with just one area of focus; it's actively expanding into new verticals like injectables, peptides, ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

Celltrion Inc. is on a biosimilar roll with the U.S. FDA this month, having gained clearance of Stoboclo and Osenvelt as products referencing Amgen Inc.’s biologic, denosumab (Prolia, Xgeva), along ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

The company emphasized its strategic focus on biosimilars, noting significant investments and a robust pipeline targeting a $200 billion market. While Alvotech highlighted successful product ...